Meng-Wei Kan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Meng-Wei Kan has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- David J. Craik
The University of Queensland
9 shared publications Daniel Feder
The University of Queensland, School of Chemistry and Molecular Biosciences, Brisbane, Qld, 4072, Australia
3 shared publications- Gerhard Schenk
School of Chemistry and Molecular Biosciences, The University of Queensland, Australia
3 shared publications - Luke William Guddat
The University of Queensland
3 shared publications - Ross Peter McGeary
School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Qld 4072, Australia
3 shared publications - Waleed M. Hussein
The University of Queensland
3 shared publications
Latest Publications
- 13 March 2025
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 64 (7) , 1437-1449
Cell-Penetrating Cyclic and Disulfide-Rich Peptides Are Privileged Molecular Scaffolds for Intracellular Targeting
Peptides that have a head-to-tail cyclic backbone tend to be more stable than linear peptides, as do peptides that contain one or more cross-linking disulfide bond. Some of these cyclic and/or disulfide rich peptides have been reported to penetrate cells. These include peptides from a wide range of natural sources, including plants, spiders, crabs, and humans. In this review we describe the structures and biophysical properties of a selected set of such peptides that have been studied in our laboratories. We further describe how they can be engineered to enhance their stability and cellular uptake, and to fine-tune selective cell entry and activity toward intracellular therapeutic targets. Examples of targets described include intracellular protein-protein interactions implicated in cancer, intracellular malarial parasites and intracellular bacterial targets. In addition to the important advances being made with these nature-inspired peptides, the rapid strides in machine learning and artificial intelligence seen over recent years promise to accelerate the use of de novo design methods to produce peptides that are able to pass through biological membranes. We describe examples where such approaches have been used to design macrocyclic peptides and peptide-drug conjugates that can penetrate cell membranes and even have significant oral bioavailability in some cases.
- 13 March 2025
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 64 (7) , 1437-1449
Cell-Penetrating Cyclic and Disulfide-Rich Peptides Are Privileged Molecular Scaffolds for Intracellular Targeting
Peptides that have a head-to-tail cyclic backbone tend to be more stable than linear peptides, as do peptides that contain one or more cross-linking disulfide bond. Some of these cyclic and/or disulfide rich peptides have been reported to penetrate cells. These include peptides from a wide range of natural sources, including plants, spiders, crabs, and humans. In this review we describe the structures and biophysical properties of a selected set of such peptides that have been studied in our laboratories. We further describe how they can be engineered to enhance their stability and cellular uptake, and to fine-tune selective cell entry and activity toward intracellular therapeutic targets. Examples of targets described include intracellular protein-protein interactions implicated in cancer, intracellular malarial parasites and intracellular bacterial targets. In addition to the important advances being made with these nature-inspired peptides, the rapid strides in machine learning and artificial intelligence seen over recent years promise to accelerate the use of de novo design methods to produce peptides that are able to pass through biological membranes. We describe examples where such approaches have been used to design macrocyclic peptides and peptide-drug conjugates that can penetrate cell membranes and even have significant oral bioavailability in some cases.
- Open Access
- 6 October 2023
- Published by CSIRO Publishing in Australian Journal of Chemistry
- Vol. 76 (10) , 655-670
Discovery and optimisation of conotoxin Vc1.1 and analogues with analgesic properties
A specimen of the marine cone snail Conus victoriae collected from a beach in Broome, Western Australia, by a group from The University of Melbourne led to the discovery of the a-conotoxin Vc1.1, which was found to have analgesic activity in rodents. The discovery of this venom-derived peptide led to a series of structural, mechanistic and pharmacological studies directed towards the development of a new analgesic for neuropathic pain by groups in Australia and internationally. Solid-phase peptide synthesis played an important role in developing structure–activity relationships. Studies in a rat model of neuropathic pain showed that a cyclic analogue of the peptide, cVc1.1, had comparable analgesic activity with that of gabapentin, one of the foremost clinically used drugs for neuropathic pain, with cVc1.1 delivered orally at a 120-fold lower dose than gabapentin. Originally, Vc1.1 was believed to act primarily through nicotinic acetylcholine receptors, but evidence for a mechanism mediated through ?-aminobutyric acid B (GABAB) receptors later emerged. Efforts to optimise the binding and pharmacological properties of analogues of Vc1.1 revealed that the affinity towards either receptor can be modulated by sequence mutations, disulfide bond modifications and backbone cyclisation. This Account describes the discovery, structure, chemistry and pharmacology of Vc1.1, with a focus on studies carried out in Australian laboratories.
- 6 October 2023
- Published by CSIRO Publishing in Australian Journal of Chemistry
- Vol. 76 (10) , 655-670
Open AccessDiscovery and optimisation of conotoxin Vc1.1 and analogues with analgesic properties
A specimen of the marine cone snail Conus victoriae collected from a beach in Broome, Western Australia, by a group from The University of Melbourne led to the discovery of the a-conotoxin Vc1.1, which was found to have analgesic activity in rodents. The discovery of this venom-derived peptide led to a series of structural, mechanistic and pharmacological studies directed towards the development of a new analgesic for neuropathic pain by groups in Australia and internationally. Solid-phase peptide synthesis played an important role in developing structure–activity relationships. Studies in a rat model of neuropathic pain showed that a cyclic analogue of the peptide, cVc1.1, had comparable analgesic activity with that of gabapentin, one of the foremost clinically used drugs for neuropathic pain, with cVc1.1 delivered orally at a 120-fold lower dose than gabapentin. Originally, Vc1.1 was believed to act primarily through nicotinic acetylcholine receptors, but evidence for a mechanism mediated through ?-aminobutyric acid B (GABAB) receptors later emerged. Efforts to optimise the binding and pharmacological properties of analogues of Vc1.1 revealed that the affinity towards either receptor can be modulated by sequence mutations, disulfide bond modifications and backbone cyclisation. This Account describes the discovery, structure, chemistry and pharmacology of Vc1.1, with a focus on studies carried out in Australian laboratories.
- 1 January 2022
- Published by Springer Nature
- p. 135-147
Cyclotides—Cyclic and Disulfide-Knotted Polypeptides
- 1 January 2022
- Published by Springer Nature
- p. 135-147
Cyclotides—Cyclic and Disulfide-Knotted Polypeptides
- 4 August 2021
- Published by Taylor & Francis in Expert Opinion on Drug Discovery
- Vol. 16 (12) , 1399-1402
How can we improve peptide drug discovery? Learning from the past
With more than 80 peptides now FDA approved and hundreds more in preclinical or clinical trials there is no doubt that peptides are having an impact in the pharmaceutical industry [1–4]. That this ...
- 4 August 2021
- Published by Taylor & Francis in Expert Opinion on Drug Discovery
- Vol. 16 (12) , 1399-1402
How can we improve peptide drug discovery? Learning from the past
With more than 80 peptides now FDA approved and hundreds more in preclinical or clinical trials there is no doubt that peptides are having an impact in the pharmaceutical industry [1–4]. That this ...
- 24 March 2020
- Published by CSIRO Publishing in Australian Journal of Chemistry
- Vol. 73 (4) , 287-299
Discovery of Cyclotides from Australasian Plants
This article is part of a special issue celebrating the contributions of Professor Paul Alewood to peptide science. We begin by providing a summary of collaborative projects between the Alewood and Craik groups at The University of Queensland and highlighting the impacts of some of these studies. In particular, studies on the discovery, synthesis, structures, and bioactivities of disulfide-rich toxins from animal venoms have led to a greater understanding of the biology of ion channels and to applications of these bioactive peptides in drug design. The second part of the article focuses on plant-derived disulfide-rich cyclic peptides, known as cyclotides, and includes an analysis of the geographical distribution of Australasian plant species that contain cyclotides as well as an analysis of the diversity of cyclotide sequences found in Australasian plants. This should provide a useful resource for researchers to access native cyclotides and explore their chemistry and biology.
- 24 March 2020
- Published by CSIRO Publishing in Australian Journal of Chemistry
- Vol. 73 (4) , 287-299
Discovery of Cyclotides from Australasian Plants
This article is part of a special issue celebrating the contributions of Professor Paul Alewood to peptide science. We begin by providing a summary of collaborative projects between the Alewood and Craik groups at The University of Queensland and highlighting the impacts of some of these studies. In particular, studies on the discovery, synthesis, structures, and bioactivities of disulfide-rich toxins from animal venoms have led to a greater understanding of the biology of ion channels and to applications of these bioactive peptides in drug design. The second part of the article focuses on plant-derived disulfide-rich cyclic peptides, known as cyclotides, and includes an analysis of the geographical distribution of Australasian plant species that contain cyclotides as well as an analysis of the diversity of cyclotide sequences found in Australasian plants. This should provide a useful resource for researchers to access native cyclotides and explore their chemistry and biology.
- Top Cited Papers
- 12 December 2019
- Published by American Chemical Society (ACS) in Chemical Reviews
- Vol. 119 (24) , 12375-12421
Cyclotides: From Structure to Function
This Review explores the class of plant-derived macrocyclic peptides called cyclotides. We include an account of their discovery, characterization, and distribution in the plant kingdom as well as a detailed analysis of their sequences and structures, biosynthesis and chemical synthesis, biological functions, and applications. These macrocyclic peptides are around 30 amino acids in size and are characterized by their head-to-tail cyclic backbone and cystine knot motif, which render them to be exceptionally stable, with resistance to thermal or enzymatic degradation. Routes to their chemical synthesis have been developed over the past two decades, and this capability has facilitated a wide range of mutagenesis and structure–activity relationship studies. In turn, these studies have both led to an increased understanding of their mechanisms of action as well as facilitated a range of applications in agriculture and medicine, as ecofriendly crop protection agents, and as drug leads or scaffolds for pharmaceutical design. Our overall objective in this Review is to provide readers with a comprehensive overview of cyclotides that we hope will stimulate further work on this fascinating family of peptides.
- 12 December 2019
- Published by American Chemical Society (ACS) in Chemical Reviews
- Vol. 119 (24) , 12375-12421
Top Cited PapersCyclotides: From Structure to Function
This Review explores the class of plant-derived macrocyclic peptides called cyclotides. We include an account of their discovery, characterization, and distribution in the plant kingdom as well as a detailed analysis of their sequences and structures, biosynthesis and chemical synthesis, biological functions, and applications. These macrocyclic peptides are around 30 amino acids in size and are characterized by their head-to-tail cyclic backbone and cystine knot motif, which render them to be exceptionally stable, with resistance to thermal or enzymatic degradation. Routes to their chemical synthesis have been developed over the past two decades, and this capability has facilitated a wide range of mutagenesis and structure–activity relationship studies. In turn, these studies have both led to an increased understanding of their mechanisms of action as well as facilitated a range of applications in agriculture and medicine, as ecofriendly crop protection agents, and as drug leads or scaffolds for pharmaceutical design. Our overall objective in this Review is to provide readers with a comprehensive overview of cyclotides that we hope will stimulate further work on this fascinating family of peptides.
- 1 November 2019
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 182, 111611
Synthesis, evaluation and structural investigations of potent purple acid phosphatase inhibitors as drug leads for osteoporosis
- 1 November 2019
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 182, 111611
Synthesis, evaluation and structural investigations of potent purple acid phosphatase inhibitors as drug leads for osteoporosis
- 14 December 2017
- Published by Royal Society of Chemistry (RSC)
- p. 302-339
CHAPTER 14. Trends in Cyclotide Research
Cyclotides are bioactive peptides from plants that have exceptional stability owing to their cyclic peptide backbone and knotted arrangement of three conserved disulfide bonds. This peptide family was first defined in 1999, although a few individual members had been identified in independent studies in earlier decades in the course of pharmaceutical screening or ethnobotanical studies. The structures, bioactivities and applications of cyclotides have been extensively reviewed elsewhere. This chapter instead provides an analysis of the trends in the cyclotide literature over the last three decades and aims to be a useful resource for following the development of the cyclotide field and for introducing new researchers to the complete literature of the field.
- 14 December 2017
- Published by Royal Society of Chemistry (RSC)
- p. 302-339
CHAPTER 14. Trends in Cyclotide Research
Cyclotides are bioactive peptides from plants that have exceptional stability owing to their cyclic peptide backbone and knotted arrangement of three conserved disulfide bonds. This peptide family was first defined in 1999, although a few individual members had been identified in independent studies in earlier decades in the course of pharmaceutical screening or ethnobotanical studies. The structures, bioactivities and applications of cyclotides have been extensively reviewed elsewhere. This chapter instead provides an analysis of the trends in the cyclotide literature over the last three decades and aims to be a useful resource for following the development of the cyclotide field and for introducing new researchers to the complete literature of the field.
- 1 January 2015
- Published by Elsevier
- p. 187-226
Natural Functions and Structure–Activity Relationships of Cyclotides
- 1 January 2015
- Published by Elsevier
- p. 187-226
Natural Functions and Structure–Activity Relationships of Cyclotides
- 1 April 2014
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 77, 248-257
Disulfide-rich macrocyclic peptides as templates in drug design
- 1 April 2014
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 77, 248-257
Disulfide-rich macrocyclic peptides as templates in drug design